A carregar...
Clinical role of brexpiprazole in depression and schizophrenia
Brexpiprazole, a serotonin–dopamine activity modulator, is the second D(2) partial agonist to come to market and has been approved for the treatment of schizophrenia and as an adjunctive treatment in major depressive disorder. With less intrinsic activity than aripiprazole at the D(2) receptor and h...
Na minha lista:
| Publicado no: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5354524/ https://ncbi.nlm.nih.gov/pubmed/28331332 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S94060 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|